Education
About Us
Working with TipRanks
Follow Us
Upstream Bio, Inc. (UPB)
NASDAQ:UPB
UPB Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
UPB Stock 12 Month Forecast
Average Price Target
$55.00
▲(259.24%Upside)
| Highest Price Target$75.00 | Average Price Target$55.00 | Lowest Price Target$35.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$15.5
Hold
1.24%
Upside
Reiterated
07/31/25
Upstream Bio, Inc. receives a moderate stock score of 54, primarily driven by its strong equity position mitigating financial risks, despite significant operational and cash flow challenges. Technical analysis shows positive momentum but warns of potential corrections due to overbought conditions. The absence of valuation metrics adds uncertainty, highlighting the need for improved financial performance.
J.P. Morgan
$35
Buy
128.61%
Upside
Reiterated
07/28/25
William Blair
―
Buy
―
Reiterated
07/28/25
Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP TreatmentWe will cover current management of patients with CRSwNP, recent updates in the CRSwNP landscape including Phase III data with Tezspire, and the design of Upstream’s Phase II study of verekitug in CRSwNP, which is reading out in the third quarter. A question-and-answer session will follow the discussion.
Piper Sandler
$75
Buy
389.88%
Upside
Reiterated
07/22/25
TD Cowen
―
Buy
―
Reiterated
05/06/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$15.5
Hold
1.24%
Upside
Reiterated
07/31/25
Upstream Bio, Inc. receives a moderate stock score of 54, primarily driven by its strong equity position mitigating financial risks, despite significant operational and cash flow challenges. Technical analysis shows positive momentum but warns of potential corrections due to overbought conditions. The absence of valuation metrics adds uncertainty, highlighting the need for improved financial performance.
J.P. Morgan
$35
Buy
128.61%
Upside
Reiterated
07/28/25
William Blair
―
Buy
―
Reiterated
07/28/25
Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP TreatmentWe will cover current management of patients with CRSwNP, recent updates in the CRSwNP landscape including Phase III data with Tezspire, and the design of Upstream’s Phase II study of verekitug in CRSwNP, which is reading out in the third quarter. A question-and-answer session will follow the discussion.
Piper Sandler
$75
Buy
389.88%
Upside
Reiterated
07/22/25
TD Cowen
―
Buy
―
Reiterated
05/06/25
Best Analysts Covering Upstream Bio, Inc.
1 Month
xxx
Success Rate
2/5 ratings generated profit
Average Return
+6.92%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +6.92% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+23.68%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +23.68% per trade.
1 Year
Success Rate
4/5 ratings generated profit
Average Return
+36.04%
reiterated a buy rating 6 days ago
Copying Matt Phipps's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +36.04% per trade.
2 Years
xxx
Success Rate
4/5 ratings generated profit
Average Return
+36.04%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +36.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
UPB Analyst Recommendation Trends
Rating
Feb 25
Mar 25
May 25
Jun 25
Jul 25
Strong Buy
2
2
2
2
4
Buy
4
4
6
8
8
Hold
0
0
0
3
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
8
13
18
Each month's total comprises the sum of three months' worth of ratings.
UPB Financial Forecast
UPB Stock Forecast FAQ
What is UPB’s average 12-month price target, according to analysts?
Based on analyst ratings, Upstream Bio, Inc.’s 12-month average price target is 55.00.
What is UPB’s upside potential, based on the analysts’ average price target?
Upstream Bio, Inc. has 259.24% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is UPB a Buy, Sell or Hold?
Upstream Bio, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Upstream Bio, Inc.’s price target?
The average price target for Upstream Bio, Inc. is 55.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $35.00. The average price target represents 259.24% Increase from the current price of $15.31.
The highest analyst price target is $75.00 ,the lowest forecast is $35.00. The average price target represents 259.24% Increase from the current price of $15.31.
What do analysts say about Upstream Bio, Inc.?
Upstream Bio, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of UPB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.